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SP-D attenuates LPS-induced formation of human
neutrophil extracellular traps (NETs), protecting
pulmonary surfactant inactivation by NETs
Raquel Arroyo1,2,3, Meraj Alam Khan3,4, Mercedes Echaide1,2, Jesús Pérez-Gil1,2* & Nades Palaniyar3,4*
An exacerbated amount of neutrophil extracellular traps (NETs) can cause dysfunction of
systems during inflammation. However, host proteins and factors that suppress NET for-
mation (NETosis) are not clearly identified. Here we show that an innate immune collectin,
pulmonary surfactant protein-D (SP-D), attenuates lipopolysaccharide (LPS)-mediated
NETosis in human neutrophils by binding to LPS. SP-D deficiency in mice (Sftpd−/−) leads to
excess NET formation in the lungs during LPS-mediated inflammation. In the absence of SP-
D, NETs inhibit the surface-active properties of lung surfactant, essential to prevent the
collapse of alveoli, the air breathing structures of the lungs. SP-D reverses NET-mediated
inhibition of surfactant and restores the biophysical properties of surfactant. To the best of
our knowledge, this study establishes for the first time that (i) SP-D suppresses LPS-
mediated NETosis, (ii) NETs inhibit pulmonary surfactant function in the absence of SP-D,
and (iii) SP-D can restore NET-mediated inhibition of the surfactant system.
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Neutrophils infiltrate into the alveolar spaces upon sensingmicrobial insults1,2. LPS is a key bacterial componentresponsible for inducing the formation of neutrophil
extracellular traps (NETs), a process generally known as NETo-
sis3–7. NETs are unique mesh-like structures made of decon-
densed chromatin fibers released by neutrophils decorated with
cytotoxic granular proteins3,8. NETosis may occur via NADPH
oxidase 2 (NOX)-dependent and NOX-independent pathways9,10.
Bacterial cell wall components (e.g., LPS) and phorbol myristate
acetate (PMA) induce NOX-mediated production of reactive
oxygen species (ROS) and subsequent NETosis7,11. Agonists (e.g.,
A23187, ionomycin) that promote calcium influx and increase
mitochondrial ROS production induce NOX-independent
NETosis. Increase in intracellular calcium also activates peptidyl
arginine deiminase 4 (PAD4) that citrullinates histone 3 (citH3),
promoting chromatin decondensation and subsequent faster
NETosis11–15. Under in vivo conditions, both forms of NETosis
could occur simultaneously due to the involvement of multiple
activators liberated during inflammation16.
Although NETs are beneficial for controlling acute infection,
excess or dysregulated NET formation is deleterious to sur-
rounding tissues and associated with lung injury and inflamma-
tory lung diseases1,17–19. The function of lung surfactant (LS),
which allows compression and expansion of alveoli during nor-
mal breathing without collapse20,21, could be compromised by the
presence of increased amounts of NETs in the airways. This is a
potential contributor to respiratory failure in lung pathologies22.
The hydrophobic surfactant proteins (SP-B and SP-C) and
phospholipids in LS are essential for surfactant biophysical
function23. By contrast, the hydrophilic multifunctional surfac-
tant proteins SP-A and SP-D present in association with lung
surfactant play key roles in the innate immune defense and
homeostasis of the lungs by interacting with various targets
(carbohydrates, DNA, neutrophils, surfactant lipids)24. There-
fore, hydrophilic surfactant proteins could protect the lungs
during inflammation by reducing the negative effect of the NETs
on lung surfactant.
In particular, SP-D recognizes various components of micro-
bial pathogens25 and participates in lung surfactant home-
ostasis26. SP-D is found as a collection of oligomeric forms27. The
protein possesses long collagen-like segments and globular heads
at the C-terminal end, which are carbohydrate recognition
domains (CRD or lectin domains). SP-D binds to LPS of certain
bacterial strains through the CRD domain in a calcium-
dependent manner28. Moreover, SP-D can interact with DNA29
and NETs30. However, it is unknown whether SP-D has a role in
modulating LPS-induced NETosis or whether SP-D could protect
LS components from potential NET-mediated inhibition. In this
study, we have investigated whether (i) SP-D suppresses NETosis,
(ii) NETs inhibit surfactant function in the absence of SP-D, and
(iii) SP-D protects LS from NET-mediated inhibition in vitro and
in vivo. Answering these questions is important for under-
standing the fundamental regulatory mechanisms of NETosis
in vivo. Furthermore, we have analyzed how NETs affect LS
biophysical function, which would be translated in vivo in the
ability to breathe with ease, and the key factors that regulate/
alleviate these complications. This study shows that SP-D is a key
regulator of NETosis and NET-related LS biophysical functions.
Results
SP-D binds LPS and suppresses LPS-mediated NETosis. SP-D
binds to LPS of certain strains of bacteria31–33. Dot blot analysis
was performed to determine the SP-D binding to LPS Escherichia
coli O182:B12. Different concentrations of LPS (2.5 to 80 μg/mL;
in a volume of 2 μL) were placed as dots on a membrane, and
incubated with 5 μg/mL or 15 μg/mL of SP-D, in the presence of 5
mM CaCl2 or 20mM EDTA. A negative control experiment was
carried out in the same conditions in the absence of SP-D. The
amount of SP-D bound to LPS was determined by developing the
dot blot after detecting the SP-D with anti-SP-D antibodies. Blot
images showed that SP-D binds to LPS O182:B12 in a dose-
dependent manner (Fig. 1a). Moreover, calcium was required for
this interaction, suggesting that SP-D binds LPS through its CRDs.
Since LPS (O128:B12) strain is different from other strains
previously tested elsewhere6, we have first determined the ability
of this LPS strain to induce NETosis (a wide range of dosage
titration) by using a SytoxGreen (cell impermeable DNA binding
dye)-based assay with human neutrophils. LPS O182:B12 induces
NETosis in a dosage dependent manner (Fig. 1b). Based on these
results, 5 μg/mL of LPS was chosen as the optimal working
concentration for most of the remaining experiments.
After determining the interaction of SP-D with LPS O128:B12,
we investigated whether the presence of SP-D could modulate
LPS-induced NETosis. For that, a SytoxGreen assay was
conducted as stated above at a 5 μg/mL LPS concentration in
the absence or presence of different concentrations of SP-D.
Before adding LPS to the cells, the agonist was incubated with SP-
D, at a final calcium concentration of 0.5 mM. The data on the
percentage of DNA release show that SP-D suppresses LPS-
mediated NETosis in a dose-dependent manner (Fig. 1c, d and
Supplementary Fig. 2).
Furthermore, we tested the effect of independently adding SP-
D and LPS to neutrophils. We first added different concentrations
of SP-D (5 or 10 μg/mL) to isolated neutrophils. The SP-D pre-
treated neutrophils were then activated by LPS, and NETosis
kinetics was assessed for 240 min (Supplementary Fig. 3). This
approach would favor the possible interaction of SP-D with the
receptors present on the neutrophils. However, LPS-mediated
NET formation was not suppressed in these SP-D pre-treated
cells. A control sample prepared as in the previous experiments
(premixing LPS and SP-D) was also added as a positive control
(Supplementary Fig. 3 “PM-LPS+ SP-D”), which showed
suppression of NETosis. Therefore, LPS-SP-D interaction is
required during the LPS-mediated suppression of NETosis.
To confirm the specificity of this effect, we conducted the
NETosis assays using other agonists. NETosis induced by other
known agonists such as PMA (NOX-dependent NETosis) or
ionomycin (NOX-independent NETosis) was not modulated by
SP-D. As neutrophils underwent NETosis in these conditions, the
percentage of DNA released was not altered by the presence of
SP-D (Supplementary Fig. 4). Therefore, SP-D-mediated suppres-
sion is specific to LPS-mediated NETosis, but it does not interfere
with PMA- or ionomycin-activated neutrophils.
Collectively, these findings show that SP-D binds to LPS
(O128:B12) in a dose-dependent manner and as a consequence,
SP-D attenuates or suppresses LPS-induced NETosis. Moreover,
calcium is required for this function. PMA- or ionomycin-
mediated NETosis is not altered by the presence of SP-D.
Imaging confirms that SP-D suppresses LPS-mediated NETo-
sis. To visualize and confirm the effect of SP-D on LPS-mediated
NET formation, we immunostained the neutrophils, that were
treated with or without LPS in the absence or presence of SP-D,
for the detection of NET markers, myeloperoxidase (MPO) and
DNA. Confocal microscopy images of neutrophils stained for
DNA (DAPI: 4′,6-diamidino-2-phenylindole; blue) and MPO
(green) confirmed that LPS induces NETosis, while SP-D sup-
presses LPS-mediated NETosis (Fig. 2). Neutrophils stimulated
with 5 μg/mL LPS showed decondensed nuclei and DNA strings
colocalized with MPO, confirming the formation of NETs. By
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contrast, the control conditions (unstimulated neutrophils)
showed intact nuclei with MPO granules in the cytoplasm. In the
presence of LPS and SP-D, NETs were almost absent and neu-
trophils morphology was similar to that of control cells. No
differences were observed in the suppressive effect at the two
calcium concentrations tested (Fig. 2a). Furthermore, based on
the neutrophil morphology and nuclei decondensation, there is
no evidence for neutrophils undergoing apoptosis/necrosis dur-
ing the suppression of LPS-mediated NETosis by SP-D. Neu-
trophils treated with ionomycin did not show any response to
SP-D, and similar amounts of NETs were observed in the pre-
sence or absence of SP-D (Fig. 2b). More cells in low magnifi-
cation images of the same panel in Fig. 2 are shown in the
Supplementary Fig. 5.
Collectively, these data confirmed the induction of NETosis by
LPS and the suppressive effect of SP-D only in LPS-mediated
NETosis, but not in the NETosis induced by other ligands such as
PMA or ionomycin (supplementary Figs. 4–5; Fig. 2).
SP-D suppresses LPS-mediated citrullination of histone 3.
Certain agonists can induce PAD4-mediated citrullination of
histone 3 to facilitate NETosis10,11,14,34. Citrullination of
histone 3 (citH3) is an important regulatory factor in NOX-
independent NETosis though some studies also reported the
involvement of citH3 in NOX-dependent NETosis. CitH3
being a regulatory factor during NETosis, we were curious to
know the potential of LPS O128:B12 to induce citrullination of
histone 3 during NETosis in the presence and absence of SP-
D. The neutrophils activated with LPS in the presence or
absence of SP-D immunostained for citH3 (red) and imaged
by confocal microscopy. Ionomycin was used as a positive
control (a well-known agonist that induces CitH3). While
staining was very low in the untreated control condition,
neutrophils treated with LPS exhibited more immunostaining
of citH3 (Fig. 3), although the staining level was slightly lower
than in the case of ionomycin (positive control). Pre-
incubation of LPS with SP-D showed reduced citH3 immu-
nostaining, indicating that the suppressive effect of SP-D
occurs during the early stages of NETosis. For single channel
and merged images, see the Supplementary Fig. 6. Interest-
ingly, the citH3 suppressive effect of SP-D was not observed
towards ionomycin treated cells (Fig. 3). Therefore, both LPS
O128:B12 and ionomycin induce citH3 in neutrophils, while
SP-D only suppresses citH3 during LPS-, but not the calcium
ionophore-induced NETosis.
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Fig. 1 SP-D binds LPS (O128:B12) and suppresses LPS-induced NETosis. a Dot blots showing that SP-D binds to LPS. LPS (O128:B12) at different
concentrations was dotted onto a membrane, which was incubated with SP-D at different concentrations in the presence of 5 mM CaCl2 or 20mM EDTA.
Human SP-D was obtained from the BAL of patients suffering from proteinosis. b–d NETosis kinetics in neutrophils isolated from healthy human peripheral
blood, as assessed by SytoxGreen plate reader assays, where the %DNA released by the cells in the presence of 0.5% (v/v) Triton was considered as
100%. b LPS dose-dependently induces NETosis. LPS at concentrations of ≥5 μg/mL induced substantial amount of NETosis. c SP-D dose-dependently
suppresses LPS (5 μg/mL)-induced NETosis (n= 3, the values shown are the average from three individual experiments performed on different days; Two-
way ANOVA with Bonferroni’s multiple comparison post-test F(8,90)= 147.7, p < 0.0001; post-test *p < 0.05). d The differences in NETosis at 240-min
time points shown in panel C (n= 3, the values shown are the average from three individual experiments performed on different days, One Way ANOVA
with Tukey’s multiple comparison post-test, F(1.477,2.953)= 27.98, p= 0.0127; *p < 0.05; **p < 0.01). Error bars represent standard deviation. See
Supplementary Fig. 4 for positive and negative controls for SytoxGreen Assay.
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LPS instillation induces more NET formation in SP-D−/−
mice. To address whether SP-D could regulate NETosis during
LPS-mediated lung inflammation, in vivo, we instilled LPS O128:
B12 into the airways of both SP-D−/− KO (knock-out) and SP-
D+/+ wild type (WT) mice. The BAL samples from these mice
were examined for the presence of DNA and citH3 to assess the
presence of NETs. Neutrophil elastase-DNA sandwich (NE-
DNA) ELISA was also performed to quantify the NETs under
these conditions. Furthermore, frozen lung tissue sections were
obtained from different groups of mice (KO and WT instilled
with LPS or PBS) to perform the immunodetection of NETs in
the lung tissue. Significantly higher citH3 was found in samples
obtained from LPS-instilled KO mice than in those from the WT
counterparts (Fig. 4a–c, Supplementary Fig. 7). PicoGreen DNA-
binding fluorescence dye was used for quantifying the DNA
present in the BAL supernatant. LPS-instilled mice contained
higher amounts of DNA in the BAL supernatant compared to
that of the PBS-instilled mice (Fig. 4d). Moreover, the DNA
concentrations were higher for LPS-instilled KO mice than for
WT counterparts. Total protein concentration determined by
BCA assay, showed no substantial differences in total protein
concentrations between LPS-instilled KO and WT mice (Fig. 4e;
p= 0.0776). In addition, quantifying NETs by the NE-DNA
based ELISA revealed a significantly higher amount of NETs in
LPS-instilled SP-D KO mice BAL samples (Fig. 4f) compared to
the other groups. Immunostaining of MPO, CitH3, and DNA in
frozen lung tissue sections demonstrated more NETs (colocali-
zation of citH3, MPO and DNA staining), in the lungs of the
LPS-instilled KO mice compared to the other groups (Fig. 5).
Collectively, these in vivo data (Figs. 4 and 5) suggest that
LPS (O128:B12) induces NETosis in mouse airways and
show that LPS-induced NETosis is reduced in mouse lungs
expressing SP-D.
Airway inflammation leads to LS dysfunction in SP-D−/−mice.
At baseline condition, SP-D deficiency in mice does not affect
the surface-active properties of lung surfactant35,36. However,
the importance of SP-D in maintaining the biophysical
properties of lung surfactant during inflammation has not been
established. Therefore, the biophysical activity of lung surfactant
(LS) obtained from BAL was evaluated in the captive bubble
surfactometer (CBS). The CBS setup mimics the in vivo situation
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Fig. 2 Immunostained confocal microscopy images confirm the suppression of LPS-mediated NETosis by SP-D. a–b Neutrophils were activated for 2 h
by LPS (a) or ionomycin (b) with or without SP-D at two calcium concentrations and imaged after immunostaining for myeloperoxidase (MPO; green) and
staining with DAPI for DNA (blue). MPO co-localized to NET-DNA upon stimulating neutrophils with LPS or ionomycin. a Pre-incubation of the indicated
concentrations of SP-D with LPS showed the suppression of NETs release. b SP-D did not suppress NETosis induced by ionomycin (n= 2, with the whole
experiment repeated twice, scale bar, 20 μm).
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Fig. 3 LPS (O128:B12) induces citrullination of Histone 3 (citH3) during
NETosis and SP-D suppresses LPS-induced citH3 formation. Neutrophils were
activated for 2 h with −ve control (media only), LPS or ionomycin with or
without 20 and 40 μg/mL of SP-D. The cells were fixed and immunostained
imaged for citH3 (red) and myeloperoxidase (MPO; green) and stained with
DAPI for DNA-blue. LPS and ionomycin, but not buffer control, induced citH3
formation that co-localized with DNA andMPO. SP-D suppressed LPS-mediated,
but not ionomycin-mediated citH3 formation (n= 2, scale bar, 40 μm).
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of a single alveolus during breathing. LS is applied onto the air-
liquid interface of an air-bubble inside a chamber filled with
buffer, which upon adsorption of the surfactant, can be com-
pressed and expanded like the alveolus is in the lung. Adsorption
of the surfactant of all the experimental groups was excellent; no
differences were observed among the different mouse groups
(Supplementary Fig. 8). When the surfactant interfacial layer
underwent repetitive compressions-expansions (dynamic cycles,
30 cycles/min), all the surfactants, except the one from LPS-
instilled SP-D KO mice, reached very low minimum surface
tensions <2 mN/m while maintaining maximum tensions
around 30 mN/m (Fig. 6), as one would expect for a well-
functioning lung surfactant37. Interestingly, LS function was
seriously compromised in KO mice instilled with LPS. LS of KO
mice with LPS-mediated lung inflammation was unable to reach
the low surface tensions during compression that are required
for efficient breathing. Also, the maximum surface tensions of
these surfactants were high in comparison to other mouse
groups (see examples of the CBS isotherms for individual mouse
samples in Supplementary Fig. 9). Considering these data, we
conclude that compared to the WT mice, biophysical activity of
surfactant of SP-D-deficient mice is compromised during lung
inflammation.
SP-A, SP-C and cholesterol do not affect LS dysfunctions.
Differences in the levels of major surfactant proteins SP-A, SP-B,
and SP-C may affect the surface activity of surfactant37. There-
fore, we analyzed the levels of these proteins present in the LS of
the four different mouse groups by Western blotting (Fig. 7a, b,
Supplementary Fig. 10). Results showed that KO mice had lower
levels of proteins SP-A and SP-C than WT mice while SP-B levels
were comparable in both SP-D-sufficient and SP-D-deficient
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Fig. 4 LPS instillation induces exacerbated DNA, CitH3, and NE-DNA in the airways of SP-D−/− KO mice. a–d, f, Higher amounts of NETs are present in
the BAL of KO mice instilled with LPS compared with the WT counterpart, as determined by (a) Western blot analyses of citH3 (complete membranes are
shown in Supplementary Fig. 7) (b) with densitometry of individual samples (c) and average data; WT-PBS (n= 6), KO-PBS (n= 7), WT-LPS (n= 7), KO-
LPS (n= 7); (Two-tailed t-test t= 3.06; *p= 0.0222) and (d) cell free DNA concentration quantified by PicoGreen assay; WT-PBS (n= 7), KO-PBS (n=
7), WT-LPS (n= 5), KO-LPS (n= 8); (One-way ANOVA with Tukey’s multiple comparison post-test, F(3,23)= 14.37, p < 0.0001; *p < 0.05; ***p < 0.001).
e Total protein concentrations in BAL for the different mouse groups; WT-PBS (n= 4), KO-PBS (n= 6), WT-LPS (n= 7), KO-LPS (n= 8); (One-way
ANOVA with Tukey’s multiple comparison post-test, F(3,21)= 2.62, p= 0.0776). f Neutrophil Elastase-DNA (NE-DNA) concentration in BAL from the
different mouse groups (n= 3-5) (One-way ANOVA with Tukey’s multiple comparison post-test, F(3,12)= 9.969, p= 0.0014; *p < 0.05, **p < 0.01). Data
are represented by individual data points and mean ± SD.
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mouse surfactant. Only SP-C levels were significantly lower when
the WT mice were instilled with LPS instead of PBS. However, no
significant changes were observed for any of the proteins as a
consequence of LPS instillation in KO mice.
Previous studies showed that phospholipid composition of
lung surfactant from SP-D-deficient and WT mice do not differ
significantly26,36. However, cholesterol content could affect the
surface properties of surfactant22,38. Therefore, we determined
the cholesterol concentration of LS. Slightly higher proportions of
cholesterol compared to PC were found in KO mice (3.3–3.7%)
than in WT mice (2-2.4%), but LPS-mediated inflammation did
not change the ratio (Fig. 7c). Therefore, the changes in other
surfactant proteins and in the cholesterol/PL ratio would not
explain the differences seen in surface activity that was
compromised only in the SP-D KO mice during LPS-mediated
inflammation.
SP-D protects surfactant from NET-mediated inhibition.
Whether NETs could directly inhibit the surface-active properties
of surfactant is unknown. Therefore, as the final step, we con-
ducted experiments to determine whether NETs could be directly
responsible for the inactivation of surfactant function, and whe-
ther SP-D could prevent such an inhibition. Organic extract (OE)
of lung surfactant purified from porcine lungs, which is depleted
of SP-A and SP-D, is used as the basic component of clinical
surfactants22. We used this surfactant as a model to study the
direct effect of NETs on the biophysical function of LS. Recon-
stituted OE material was combined with purified NETs obtained
from neutrophils and its biophysical activity was evaluated in the
CBS. NETs completely inhibited the surfactant function, even
though the concentration of NETs applied was lower than the
ones found in vivo in the BAL of KO LPS-instilled mice. As
expected37, surface tension of the control surfactant reached ~20
mN/m after initial interfacial adsorption (IA). By contrast, in the
presence of NETs, surface tension after adsorption was still high,
in the order of ~50 mN/m (Fig. 8 and Supplementary Table 1).
The addition of SP-D fully overcame the inhibitory effect of the
NETs as observed in our experiments and brought the surface
tension to values comparable to those produced by surfactant
without the NETs.
NETs also affected the dynamic behavior of surfactant, and
minimum and maximum surface tensions reached during
dynamic cycles were high, far from the minimal values of ≤2
mN/m and ~25mN/m, respectively, typically produced by a good
surfactant film. SP-D was also found to counteract the inhibitory
effect of NETs on the dynamic behavior of surfactant (Supple-
mentary Table 1). These experiments collectively showed that
NETs directly inhibit the biophysical function of lung surfactant,
and that SP-D can protect LS against the surface tension
inhibitory effects of the NETs.
NETs impair lateral packing of lung surfactant membranes. To
determine how NETs affect lung surfactant biophysical function,
the structure of the LS film subjected to compression at the air-
water interface was observed in the presence and absence of
NETs. Experiments were conducted in a Langmuir surface bal-
ance, doping surfactant OE with a trace of unsaturated phos-
pholipids and SP-B that were fluorescently labeled with
Rhodamine-DOPE and Alexa488, respectively. Figure 9 shows
how NETs induce a profound alteration of the structure of the LS
film at the air-water interface. Under control conditions (absence
of NETs, Fig. 9a), surfactant films exhibited good compressibility,
with compression inducing the segregation of probe-excluding
highly packed domains (black regions) likely enriched in satu-
rated phospholipids. Condensed domains are required to achieve
low surface tensions during surfactant film compression23.
However, in the presence of NETs (Fig. 9b), these domains were
not observed in surfactant films subjected to compression, indi-
cating that the LS films were not able to properly sort saturated
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Fig. 5 LPS-induced NETosis is high in the lungs of KO mice compared to
WT mice. Lung tissue sections were obtained from KO and WT mice that
were instilled with either PBS or LPS. Tissue sections were processed,
immunostained and imaged for citH3 (red) and myeloperoxidase (MPO;
green) and stained with DAPI for DNA (blue). NETosis was absent in mice
instilled with PBS. KO mice instilled with LPS exhibited more NETs in lung
tissue, compared to the WT mice instilled also with LPS. (n= 2; scale
bar, 23 μm).
0
10
20
30
40
WT
PB
S
KO
 PB
S
WT
 LP
S
KO
 LP
S
20
30
40
50
60
70
WT
 PB
S
KO
 PB
S
WT
 LP
S
KO
 LP
S
02elcyC1elcyC
γ m
ax
(m
N
/m
)
γ m
in
(m
N
/m
)
**
*
****
****
** ***
Dynamic cycles
Fig. 6 Pulmonary surfactant of LPS-instilled SP-D−/− (KO) mice show
surfactant dysfunction. Minimal (γmin) and maximum (γmax) surface
tensions of LS (10mg/mL) from the different mouse groups during
compression-expansion cycling. Symbols represent data obtained from
individual mouse (average of three replicates). WT-PBS (n= 7), KO-PBS
(n= 7), WT-LPS (n= 9), KO-LPS (n= 11); (One-way ANOVA with Tukey’s
multiple comparison post-test, Cycle 1 (γmin) F(3,30)= 5.547, p= 0.0038;
Cycle 20 (γmin) F(3,30)= 15.95, P < 0.0001; Cycle 1 (γmax) F(3,30)=
3.275, p= 0.0346; Cycle 20 (γmax) F(3,30)= 11.62, p < 0.0001; post-test
**p < 0.01; ***p < 0.001; ****p < 0.0001). Supplementary Fig. 8: initial
adsorption of LS of all the experimental mouse groups. Supplementary
Fig. 9: individual examples of the CBS isotherms for individual mouse of all
experimental groups.
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from unsaturated phospholipid species at the air-water interface.
The absence of tightly packed phospholipid domains competent
to provide maximal stability at very highly compressed states
correlates with the inability of these films to reach low enough
surface tensions. No differences were observed in the apparent
distribution of SP-B between the two conditions. Fluorescently-
labeled SP-B appeared homogenously distributed within the
expanded regions of the films. Thus, exposure to NETs affects the
re-organization of phospholipids that occurs during the com-
pression of surfactant films, and that is required for the films to
reach the maximal packing associated with the minimal surface
tensions.
Discussion
SP-D plays an important role in the immune defense of the lungs
and in LS homeostasis25. Studies have shown the involvement of
NETs during lung inflammation30,39,40. Douda et al. have shown
that SP-D directly interacts with NETs and bacterial surfaces,
simultaneously30. However, whether binding of SP-D to LPS
would suppress LPS-mediated NETosis was unknown. Also,
whether NETs could inhibit surface tension-lowering properties
of surfactant and the ability of SP-D to protect NET-mediated
surfactant inhibition was also unknown. In this study, we have
demonstrated that (i) SP-D dose-dependently attenuates LPS
(O128:B12)-induced NETosis; (ii) NETs inactivate lung surfac-
tant, and (iii) SP-D can protect surfactant from NET-mediated
inactivation during breathing-like interfacial mechanics. There-
fore, we have identified novel functions for SP-D:LPS, SP-D:NET,
and SP-D:lung surfactant interactions and revealed the
mechanistic relevance of these interactions in regulating airway-
related pathobiological functions.
Palaniyar et al. identified the interaction between several
collectins, including SP-D, and DNA29. Douda et al. further
showed that SP-D avidly binds to NETs, and interconnects
bacteria with NETs30. These studies suggest that the col-
lagenous domains of SP-D interact with DNA and NETs
whereas globular lectin domains bind bacteria. It has been well
established that SP-D binds to several carbohydrate ligands,
including LPS from different strains of bacteria via its lectin
domains28,33. Previous studies have shown that LPS from dif-
ferent bacterial strains induce NETosis to different
degrees6,41,42. Our data show that SP-D recognizes LPS (O128:
B12) in a calcium-dependent manner (Fig. 1a), which is a
hallmark of SP-D recognizing carbohydrate ligands via its lectin
domain31,43,44. LPS (O128:B12) induces NETosis in a dose-
dependent manner, and when this LPS was pre-incubated with
SP-D, SP-D dose-dependently inhibit the LPS-mediated
NETosis (Fig. 1b–d). This effect is specific for LPS, and SP-D
does not inhibit the NETosis induced by other agonists (e.g.,
PMA, ionomycin). This inhibitory effect is confirmed by
immunofluorescence microscopy (Fig. 2). In addition, both the
doses and strains of LPS can affect the level of NET
formation6,45,46. This LPS (O128:B12) also induces citH3 for-
mation that is useful for some forms of NETosis, and this effect
is also prevented upon binding of SP-D to LPS (Fig. 3).
Therefore, SP-D binds to LPS and inhibits LPS-mediated
NETosis.
Previously, a mouse model has been established to study the
NETosis in vivo30,47. Saffarzadeh and colleagues reported the
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presence of NETs in lung sections from mice in a model of lung
injury induced by LPS. Co-localization of NE, histones and DNA
was shown by immunostaining of the lung sections in WT
mice47. Another study reported the increased level of SP-D in the
BAL of WT mouse (instilled with LPS), compared to WT mouse
instilled with PBS. This increase in SP-D concentration was
associated to the increase in neutrophils infiltration into the
airways30, indicating a probable direct relationship between SP-D,
neutrophils and NETosis. When LPS (O111:B4) was instilled into
the airways of mice, neutrophil count peaked at 1–2 days post
instillation. When LPS (O128:B12) was instilled, we could see a
clear difference in the NETosis levels on day 1-post LPS instil-
lation between WT and SP-D KO mice (Figs. 4 and 5). SP-D KO
mice generated more NETs, as determined by NE-DNA, immu-
nostaining of frozen lung sections, citH3 and DNA levels.
Therefore, SP-D deficiency is associated with increased NETosis
in vivo. This finding is consistent with the ability of SP-D to bind
LPS and suppress NETosis, ex vivo (Figs. 1–3). It is important to
note that the lack of SP-D in the KO animals is associated with a
somehow higher intrinsic pro-inflammatory status. Therefore, the
higher level of neutrophil infiltration and NETosis could be a
consequence of many factors beyond SP-D deficiency. However,
previous studies showed that SP-D levels increase after LPS
instillation30; hence, the contribution of SP-D-mediated sup-
pression of LPS-induced NETosis may even be enhanced in vivo.
Notably, inflammatory lung diseases such as acute respiratory
distress syndrome or, cystic fibrosis are associated with
exacerbated NETosis, and have low levels of SP-D in the
airways1,25,47–49. Therefore, lack of enough SP-D might be an
additional factor to increase the deleterious effect of inflammation
in some respiratory pathology, as a consequence of possibly
exacerbated NETosis.
The negative effects of excess NET formation upon lung
inflammation and injury have been highlighted by us and
others1,16,47,50,51. One of the previous studies showed that NETs
may be a contributor to the reduction in lung function and
compliance in a double hit model (mechanical ventilation+
O111:B4 LPS)52. However, whether NETs could impair lung
surfactant biophysical function was unknown. The present data
show that SP-D deficiency in mice results in a severe surfactant
inactivation during LPS-mediated inflammation (Fig. 6). In the
presence of SP-D (WT mice) instillation of LPS did not show
apparent effects on the biophysical behavior of LS isolated from
these mice. Probably, higher doses of LPS to induce greater
NETosis and acute lung injury, or longer times than 24 h, are
needed to see a perturbation in the LS biophysical behavior in
WT mice, compared with the conditions selected in this study,
which are the described in a previous in vivo model of NETosis30.
In vitro experiments conducted with surfactant lipids and dif-
ferent concentrations of SP-A suggested a potential role for SP-A
in regulating surface active properties of surfactant53. However,
studies conducted with SP-A-deficient mice and using higher
concentrations of surfactant lipids relevant to the context of
airways established that SP-A does not have a significant role in
regulating surface tension or protecting surfactant from inacti-
vation by various inhibitors54–56. Nevertheless, we have analyzed
the levels of SP-A in the surfactant from the WT and SP-D
deficient mice (Fig. 7). SP-A levels were lower in the SP-D defi-
cient mice, as previously reported35, but SP-A levels did not
change during LPS-mediated inflammation (Fig. 7). Therefore,
SP-A is less likely to contribute directly to the effects seen in our
in vivo and in vitro studies. SP-B and SP-C are the surfactant
proteins with more direct participation in surface tension redu-
cing properties of surfactant23,37. Their levels also would not
explain the differences in the surface activities seen in our studies,
because the levels of these proteins were comparable in the KO
mice exposed to PBS and LPS conditions.
Cholesterol/PL ratio is another factor that could affect surface
tension and that has been identified as a pathogenic factor in lung
diseases22,38. We found that the ratio is higher in the surfactant
isolated from SP-D-deficient mice (Fig. 7c). However, the ratio is
similar in the LS with or without LPS-mediated inflammation.
Moreover, cholesterol concentrations in KO mice were lower than
the concentrations that have been reported to cause surfactant
inhibition38. Therefore, cholesterol content does not seem to be a
contributory factor to LPS-induced surfactant dysfunction. Serum
proteins have been reported to inhibit LS57, but total protein
concentrations in BAL from our LPS-instilled mice were low
compared to the concentrations that were reported to cause
inhibition58. Therefore, although other factors (e.g., ROS, pro-
inflammatory mediators) may contribute to LS dysfunction,
based on our results we propose that NETs directly inhibit LS
biophysical function, at least in this in vivo model. Alterations in
surfactant composition as a consequence of the lack of SP-D (and
the concomitant lack of an appropriate recycling and renewal of
spent surfactant35,59), could also lead to a complex that could be
more susceptible to inactivation, by NETs and/or by other inhi-
bitory substances. Lack of SP-D in vivo could then simultaneously
contribute to several surfactant-related pathogenic factors, either
directly—as a consequence of the lack of protection imparted by
SP-D binding- or indirectly—via the alteration of surfactant
composition and structure resulting from impaired recycling.
Nevertheless, our complementary in vitro studies identified a
direct inhibitory effect of NETs in LS performance, which can be
SP-D
NETs − + +
− − +
IA
Dyn
Fig. 8 NETs inhibits surface-active properties of pulmonary surfactant,
and SP-D mitigates the inhibitory effect of NETs on surfactant. Surface
activity is assessed by the isotherms obtained from the CBS, thermostated
at 37 °C. Representative isotherms from each group of samples are shown.
Surfactant films were formed upon injection of a suspension of surfactant
(20mg/mL) with or without NETs, in the absence or presence of SP-D
(0.67% w/w with respect to phospholipid). The upper set of isotherms
show IA to the air-water interface of a bubble over a 5-min period. The
lower set of isotherms illustrates dynamic compression-expansion cycling
(at 20 cycles/min) for cycles 1, 10 and 20. The detail parameters are
enlisted in Supplementary Table 1.
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prevented by the mere presence of SP-D (Fig. 8). This inactivation
is associated with a profound alteration of the lateral structure of
interfacial surfactant films that is competent to produce the
lowest surface tensions at the end of compression. Exposure to
NETs prevents the compression-driven segregation of condensed
domains, presumably enriched in saturated phospholipid species,
which are the hallmark of functional lung surfactant films60–62
(Fig. 9). It is plausible that the inhibition of LS biophysical
behavior could be mediated by the DNA component of NETs,
which might disrupt the lateral packing of surfactant membranes
and the organization of the different protein and lipid species at
the interface, particularly those charged at physiological pH, as a
consequence of its polyanionic character. Therefore, the ability of
SP-D to interact with DNA29 could be important for its direct
protective effect, besides its anti-inflammatory actions mediated
via LPS scavenging. Interestingly, we found comparable levels of
surfactant inactivation by different preparations of NETs that
were always dosed considering the DNA content, supporting that
DNA is the most active component with regard to surfactant
inhibition.
Considering all the data, we propose a key role for SP-D in
modulating NETosis and contributing to protect the lung and the
pulmonary surfactant system. SP-D binds to LPS and reduce LPS-
mediated NETosis. In the absence of SP-D, neutrophils might
undergo NETosis to a greater extent that results in higher
amounts of NET accumulation at the alveolar spaces and its
interaction with and perturbation of the surfactant layer. NET-
surfactant interactions could lead to a profound disruption of the
multilayered surfactant structure and a subsequent impairment of
the surface active functions of the surfactant. When SP-D is
present, interactions between the NET and SP-D could reduce
NET-mediated inactivation of surfactant (Fig. 10). Therefore, SP-
D could play a dual protective role, as an important inhibitor of
LPS-mediated NET formation and as an inhibitor of NET-
mediated surfactant inactivation during lung inflammation. It is
important to consider though that the actual scenario in vivo has
additional complexities. Differences in the level of SP-D could not
only have consequences on the level of NETosis in the presence of
LPS, but as a consequence of different processes related with the
higher pro-inflammatory contexts associated to low levels of the
collectin. Low SP-D level scenarios also imply defective surfactant
recycling and potentially accelerated compositional and func-
tional impairing, which may results in surfactant complexes that
are intrinsically more susceptible to inactivation by many agents
including NETs. Total or partial inactivation of surfactant, and
the subsequent defective breathing mechanics, is a recognized
additional lung pro-inflammatory contribution, which may
induce further compromise of alveolar homeostasis. Hence, SP-D
may be a potential therapeutic candidate for minimizing surfac-
tant inhibition in inflammation-related multi-factorial respiratory
pathologies.
Methods
Ethics statement. Human and animal study protocols were approved by the
Research Ethics Board (REB) of the Hospital for Sick Children, Toronto, Canada.
Donors signed the consent form prior to the participation. In addition, all animal
protocols were approved by the Toronto Centre for Phenogenomics (TCP) (Tor-
onto, Canada), and all the procedures were performed according to the protocols
and ethical guidelines.
Human peripheral neutrophil isolation. Peripheral blood from healthy male
donors was collected in K2 EDTA blood tubes. We exclude blood collection from
any healthy donor having flu or any known inflammatory symptoms. Isolation of
neutrophils was carried out as described previously6,46,63. Briefly, PolymorphPrep
(Axis-Shield) was used for isolating polymorphonuclear neutrophils from blood.
Red blood cells were then lysed and cellular debris were eliminated using con-
secutive washes as stated previously (see references for details). Purified neutrophils
were resuspended in RPMI medium (Invitrogen) containing 10 mM HEPES (pH
7.2). Cells were counted and viability was checked by Trypan blue using a
hemocytometer. Purity of neutrophils was determined by Cytospin preparation
and imaging. Neutrophil preparations with >95–98% pure viable cells were used in
this study.
Control +NETs
Rhodamine Alexa488 Rhodamine Alexa488
A B
Fig. 9 NETs impair the structure and lateral packing of phospholipids in interfacial lung surfactant films. Lung surfactant was labeled with a trace of
fluorescent Alexa488-labeled surfactant protein SP-B (F-SP-B, 1% (w/w) with respect to lipids) and with rhodamine-DOPE (0.1% mol/mol probe/
phospholipid) in the presence or absence of purified NETs. The surfactant was then applied onto the air-water interface of a Langmuir surface balance and
the films formed were compressed to a surface pressure of 30mN/m. The compressed films were finally transferred to glass cover slips and analyzed
under the epifluorescence microscope. a In the absence of NETs (control), compressed lung surfactant films segregate probe-excluding highly-packed
domains enriched in saturated phospholipids, which are necessary to reach the lowest surface tensions. b In the presence of NETs, condensed phospholipid
domains are not observed, being the structure and lateral packing of the lung surfactant film severely impaired. Scale bar, 25 μm.
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NETs preparation and purification. Human neutrophils (100,000) in 1 mL of
RPMI media were stimulated with 5 μg/mL LPS (O182:B12) from Escherichia coli
(Sigma) to induce NETosis. Samples were incubated for 4 h at 37 °C in 5% CO2
with intermittent gentle mixing by inverting the tubes (once each 30 min), in order
to avoid cell sedimentation. After incubation, samples were centrifuged at 400×g
for 10 min. Supernatants were collected and snap-frozen in dry ice. DNA con-
centration in the purified NETs was determined with Quant-iTPicoGreen dsDNA
Kit (Invitrogen) following manufacturer´s instructions.
SP-D purification. Human SP-D was obtained from therapeutic bronchoalveolar
lavage (BAL) of individuals with pulmonary alveolar proteinosis. The purified hSP-
D from these BALs has been used in many functional studies as reported
earlier64,65. Briefly, BAL was incubated with maltose-agarose beads in the presence
of 10 mM CaCl2. The beads were poured into an empty column and washed with 1
M NaCl to remove non-specifically bound components on an AKTA FPLC system
(G.E. Healthcare). SP-D was eluted with Tris-MnCl2 buffer (20 mM Tris (pH 7.4),
100 mM MnCl2). Then, fractions containing SP-D were pooled and concentrated,
and further purified with a Superose 6 (10 × 300 mm) gel filtration column in 20
mM Tris (pH 7.4), 150 mM NaCl, 5 mM EDTA buffer, as previously described64,65.
The oligomeric structural intactness of the purified SP-D from the BAL of pro-
teinosis patients has been assessed by electrophoresis and atomic force microscopy
(AFM)27. The AFM images show that hSP-D purified from proteinosis preserves its
typical oligomeric structure, assembled as large oligomers (Supplementary Fig. 1).
Routine functional experiments confirm that this protein preparation retains the
ability to bind and agglutinate bacteria (i.e., E. coli).
SytoxGreen NETosis assay. SytoxGreen (Life Technologies), a cell-impermeable
nucleic acid binding dye, was used for monitoring NETosis over time. Microplates
of 96-wells were seeded with 100 μL of a suspension containing 50,000 neutrophils
and 5 μM SytoxGreen dye in each well. Agonists (known NETs inducers; positive
control), or agonists with SP-D (at 10, 20, 40 μg/mL), or RPMI with SP-D buffer
(negative control) were prepared in 10 μL of media and incubated for 30 min at 37 °
C in 5% (v/v) CO2 incubator. Calcium concentration of SP-D buffer was adjusted
prior to use at 5 mM CaCl2. After incubation time, a volume of 10 μL, suspension
containing buffer alone (negative control), or agonist (with and without SP-D) was
added to the cells and the fluorescence intensity of the dye was tracked at 30-min
time intervals up to 240 min after neutrophil activation, using a POLARstar
OMEGA fluorescence plate reader. Between readings, the plates were kept at 37 °C
in 5% (v/v) CO2 incubator. Final calcium concentration in the experiment was 0.5
mM. The final concentrations of the different agonists in these experiments were
25 nM PMA, 2.5 μM ionomycin (calcium ionophore produced by the bacterium
Streptomyces conglobatus) and 5 μg/mL LPS. For LPS dose-response, different LPS
concentrations were titrated. The background fluorescence at 0-min time point was
subtracted from the fluorescence at each time point and was then divided by the
fluorescence values of the neutrophils lysed with 0.5% (v/v) Triton X-100 (the
maximum fluorescence in the neutrophils treated with Triton X-100, considered as
100% DNA release).
Immunostaining and confocal imaging. Neutrophils (50,000 in 100 μL of RPMI
media/well) were seeded in 12-well chamber slides (Ibidi). The agonists and con-
trols with or without SP-D prior adding to neutrophils were prepared as described
above. In this case, two final calcium concentrations (0.5 mM and 2 mM) were
tested. After stimulation, neutrophils were placed at 37 °C, 5% CO2 incubator for 2
h. Cells were then fixed with 4% (w/v) PFA for overnight at 4 °C. After fixation,
samples were washed three times with PBS and permeabilized with 0.05% (w/v)
Triton X-100 for 10 min. Cells were washed three times with PBS again. For non-
specific antigen blocking, 4% (w/v) BSA were used for 1 h. After blocking, primary
antibodies were added to the samples and incubated overnight (ON) at 4 °C. The
antibodies used were anti-myeloperoxidase mouse antibody (ab25989, Abcam) at
1:500 for staining myeloperoxidase (MPO) (with anti-mouse secondary antibody
conjugated with a green fluorescence Alexa fluor 488 dye; 1:5000 dilution; Ther-
moFisher), while rabbit anti-citH3 antibody (ab5103; Abcam) at 1:500 dilution was
used for detecting the presence of citrullinated histone H3 (CitH3, with anti-rabbit
secondary antibody conjugated with a far-red fluorescence dye Alexa fluor 647;
1:5000 dilution; ThermoFisher). DNA was stained with DAPI (4’,6-diamidino-2-
phenylindole) (1:100 dilution of the stock 1 mM). After incubation with the sec-
ondary antibody, slides were washed and mounted in glass cover slips (Thermo-
Fisher) with anti-fade fluorescent mounting medium (Dako). The images were
taken using an Olympus IX81 inverted fluorescence microscope with a Hamamatsu
C9100-13 back-thinned EM-CCD camera and Yokogawa CSU × 1 spinning disk
confocal scan head with Spectral Aurora Borealis upgrade, four separate diode-
pumped solid-state laser lines (Spectral Applied Research, 405, 491, 561, and
642 nm). Samples were imaged at ×40/0.95 magnification and images were pro-
cessed by Volocity software (version 6.3, Cell Imaging Perkin-Elmer).
Dot Blot. LPS (O182:B12) dilutions at 2.5, 5, 10, 20, 60, and 80 μg/mL were dotted
(2 μL) onto a nitrocellulose membrane (Amersham Biosciences). SP-D (370 ng)
and SP-D buffer were also applied as positive and negative controls, respectively.
After drying at room temperature (RT), membranes were blocked with 5% (w/v)
BSA in TBST-Ca buffer (50 mM Tris (pH 7.4), 150 mM NaCl, 0.02% (v/v) Tween
and 5 mM CaCl2) overnight at 4 °C. Three washes with TBST-Ca buffer were done
and the different membranes were incubated with 5 μg/mL or 15 μg/mL of SP-D in
TBST-Ca or 5 μg/mL of SP-D in TBST-EDTA (20 mM) for 5 h at RT. A control set
with TBST-Ca without SP-D was also performed. After incubation, membranes
were washed four times with TBST-Ca and incubated with SP-D antibody against
human recombinant SP-D (custom polyclonal anti-SP-D generated in rabbits by
Cocalico Biologicals, PA, USA)66 at 1 μg/mL ON at 4 °C, followed by four washes
with TBST-Ca. Membranes were then incubated for 1 h with the secondary anti-
body, donkey anti-rabbit IgG-HRP (ThermoFisher; 1:10000) and washed as
described above. SP-D complexes were detected by ECL (Millipore).
Mice and BAL sample processing. Balb/c wild type (WT) SP-D+/+ and Knock out
(KO) SP-D−/− mice (generated by Dr. S. Hawgood, UCSF) were bred in the Toronto
Centre for Phenogenomics (TCP), Canada. For airway instillation, mice were anes-
thetized with 2–4% (v/v) isofluorane with O2 at 1 L/h. Then, 5 μg of LPS (O182:B12)
in 25 μL of sterile PBS or 25 μL of sterile PBS (negative control) were instilled
intranasally. Mice were sacrificed with an intraperitoneal injection of 0.1mL of
Euthanyl (Bimeda-MTC) 24 h after instillation, and three times with 1mL of buffer
(Tris 5 mM (pH 7.4), NaCl 150mM) were used to flush the lungs. All procedures
were performed in accordance with TCP approved protocols and ethical guidelines.
BAL samples were frozen with dry ice and stored until use at −80 °C. Prior to use
each sample was thawed at 37 °C and centrifuged for 10min at 400×g, discarding the
pellet. An aliquot of 400 μL of BAL supernatant was saved and frozen for further
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Fig. 10 A model summarizing the effect of SP-D on LPS-mediated NETosis and NET-mediated inhibition of surfactant. In the presence of SP-D (+SP-D),
SP-D sequesters LPS and suppresses LPS-mediated induction of NETosis; any NETs formed by the neutrophils will be coated with SP-D. These two effects
of SP-D would suppress NET formation and NET-mediated inactivation of lung surfactant. In this case, lung surfactant would present a functional structure,
exhibiting saturated phospholipid domains (dark blue), which are necessary to reach very low surface tensions when the monolayer is compressed. In the
absence of SP-D (−SP-D), LPS would directly interact with neutrophils and induce NETosis. NETs released from these neutrophils will inhibit the surface-
active properties of the surfactant, disrupting the phase separation and organization of phospholipids at the interface, being unable to form highly packed
domains. Our data sets indicate that SP-D significantly contributes to the protective effects seen in our in vitro, ex vivo, and in vivo experiments.
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experiments (determination of CitH3 and total protein, DNA and NE-DNA ELISA in
BAL). Two mililiter of BAL supernatant aliquots were ultra-centrifuged at 100,000×g
(4 °C, 1 h) to pellet lung surfactant components. Surfactant pellets were resuspended
in 10–15 μL of buffer (Tris 5mM (pH 7.4), NaCl 150mM). Phosphatidylcholine (PC),
as a reference for phospholipids (PL) concentration, and cholesterol in lung surfactant
samples were determined using kits (Spinreact) based on enzymatic methods67,68.
Samples were tested in the captive bubble surfactometer (CBS) at a concentration of
10mg/mL of PC.
Total protein and DNA concentrations were determined in BAL supernatants.
Pierce BCA Protein Assay Kit (ThermoFisher) was employed to determine total
protein concentration in the samples. Quant-iTPicoGreen dsDNA Kit (Invitrogen)
was used for obtaining DNA concentration in BAL supernatants, and in this case,
samples were diluted 1:3, and 50 μL of the diluted samples were assayed.
Manufacturer’s instructions for 96-wells plate protocols were followed for both
commercial kits.
Neutrophil elastase (NE)-DNA ELISA. All the BAL samples, from WT and SP-D
KO mice instilled with LPS or vehicle control (PBS), were analyzed for neutrophil
elastase-DNA (NE-DNA) complex using a sandwich ELISA protocol. A volume of
100 μL of undiluted samples were added in duplicate to a 96-well plates, which
were pre-coated with anti-neutrophil elastase antibodies (MyBioSource). The plates
were sealed and incubated for 90 min at 37 °C. After the incubation, wells were
washed three times by using 350 μL 1× washing buffer. After washing without
dehydrating the wells, a volume of 100 μL of anti-DNA antibody was added to each
well (diluted 1:100 in incubation buffer; Roche, catalog #11774425001). The plates
were again sealed and incubated for 2 h on a rocker at room temperature. After the
incubation wells were again washed, and 100 μL of ABTS substrate (MyBioSource,
catalog #MBS269576) was added to each well. After substrate incubation for 30 min
at room temperature in the dark, the reactions were stopped by adding the ter-
mination solution and the absorbance values were read at 405 nm using a plate
reader. NETs prepared from human neutrophils with PMA activation were
quantified (DNA content) and ran as a control to build a standard-curve.
Immunolocalization of CitH3 and MPO in frozen lung section. SP-D KO and
WT mice were instilled with either PBS control or LPS. After 24 h, lungs were
perfused with 1mL of optimal cutting temperature (OCT) compound (Tissue-Tek;
Sakura Finetechnical Co., Ltd., Tokyo, Japan) through trachea. After tying off the
trachea to maintain the fluid in the lung, the whole lung was further emerged into the
OCT and preserved at −80 °C. Frozen lungs were cut as 10 μm sections in a cryostat
microtome and mounted on glass slides. Lung tissue sections from different groups
(WT and KO mice, instilled with either PBS or LPS) were thawed at room tem-
perature and fixed in 4% (v/v) paraformaldehyde for 15min. After washing, sections
were treated with 5% (w/v) BSA for 1 h at room temperature to block the nonspecific
binding. Rest of the immunostaining steps and confocal imaging were followed as
stated above (see section “Immunostaining and confocal imaging”).
Reconstituted porcine surfactant extract. Organic extract (OE) from native
surfactant purified from porcine lungs was obtained as previously described by
Schürch and colleagues37. A volume of 335 μL of OE at 8.97 μg/μL were evaporated
under nitrogen flow and then under vacuum in an UNIVAP at 37 °C, for 2 h to
remove traces of organic solvents. Samples were reconstituted to 60 mg/mL final PL
concentration in a two-step process: (i) first, 25 μL of buffer 5 mM Tris (pH 7.4),
150 mM NaCl were added and incubated at 45 °C for 30 min; (ii) then, 25 μL of
purified NETs in RPMI media with a DNA concentration of 0.65 μg/mL were also
added and incubated again at 37 °C for another 30 min. All incubations in the
reconstitution process were performed with intermittent shaking (10 min shaking/
10 min repose; 1400 rpm in a Thermomixer). For recovering experiments, the 25
μL of buffer in reconstitution step 1 were substituted by 25 μL of SP-D at 808 μg/
mL (final SP-D concentration in the sample respect to lipids was 0.67% (w/w)).
Samples were diluted to 20 mg/mL PL concentration with purified NETs in RPMI
media and incubated 30 min at 37 °C prior to use. RPMI media alone was used as a
control to identify any effect produced by the RPMI media vehicle.
Captive bubble surfactometer (CBS). The CBS is a device that allows evaluating
the biophysical function of lung surfactant in vitro69. This device creates an
environment that mimics the situation of a single alveolus in the lung56,69,70. A
small air-bubble was created inside a chamber filled with buffer (150 mM NaCl, 5
mM Tris (pH 7.4), and 10% (w/v) sucrose). The sample to be tested (150 nL) was
applied with a capillary inside the chamber near the surface of the bubble.
Adsorption of the material to the air-water interface was thus evaluated during the
initial adsorption (IA) period. The shape of the bubble was monitored and
recorded for 5 min to observe changes in the surface tension (γ). After adsorption,
the chamber was sealed. Compression-expansion cycles of the bubble at 20 cycles/
min were then carried out to evaluate the dynamic behavior of the surfactant.
These cycles mimic the situation in the alveoli during breathing, while lungs are
inflated and deflated during air inspiration and expiration, respectively.
To test the samples from mice, 30 dynamic cycles were carried out at 30 cycles/
min, which is the maximum speed allowed by the CBS device, even though mice
breathing frequency is higher. Three replicates were performed of each isolated LS,
and the average surface activity of the replicates was represented in the graphs.
Surface balance. To observe and analyze the lateral structure of interfacial surfactant
films, surfactant suspensions were spread onto a buffered (150mM NaCl, 5mM Tris
pH 7.4) sub-phase in a Langmuir surface balance equipped with a continuous Teflon
ribbon barrier and a 200 cm2 trough (Nima Technology, Coventry). Organic extract
from native surfactant was purified from porcine lungs as previously described, and
doped with a trace of Alexa488 (Invitrogen) fluorescently-labeled surfactant protein
SP-B (F-SP-B, 1% (w/w) with respect to lipids). The sample was dried under nitrogen
flow and then under vacuum in an UNIVAP at 37 °C, for 2 h to remove traces of
organic solvents. The mixture was reconstituted to 10mg/mL final PL concentration
with buffer 150mM NaCl, 5mM Tris pH 7.4. Then, it was labeled with rhodamine-
DOPE (Avanti Polar Lipids, Inc.) (0.1% mol of probe/mol of phospholipid each,
added in a trace of dimethyl sulfoxide) in the presence or absence of 20 μL of purified
NETs in RPMI media with a DNA concentration of 0.65 μg/mL, at 37 °C for 1 h with
intermittent shaking (10min shaking/10min repose; 1400 rpm in a Thermomixer),
taking the surfactant suspension to a final PL concentration of 5mg/mL. Drops of the
surfactant suspension were finally deposited onto the surface of the aqueous sub-
phase in the surface balance until a surface pressure of 2mN/m was achieved. After
10min to allow the material to stabilize, the interfacial film was compressed at 65
cm2/min to a final target pressure of 30mN/m. After 10min of further equilibration,
Langmuir–Blodgett films were prepared by transferring the interfacial films onto glass
cover slides using the COVASP method as described elsewhere69 at a transfer rate of
25 cm2/min, thus allowing the correct transference without altering the structure of
the surfactant layers. Epifluorescence microscopy images were obtained in a Leica DM
4000B microscope, equipped with a camera Hamamatsu Orca-R2.
Western blotting (WB). Samples for WBs of lung surfactant proteins were pre-
pared by applying 10 μg of surfactant PC per sample. Samples to analyze SP-A and
SP-C were loaded under reducing conditions using Laemmli buffer as loading
buffer71 containing 4% (v/v) β-mercaptoethanol; analysis of SP-B was performed
under non-reducing conditions. Samples were boiled at 99 °C, 10 min. They were
loaded in 16% (w/v) or 4-20% (w/v) acrylamide gels and later transferred onto a
PVDF membrane for 1 h at 300 mA. Membranes were blocked with 5% (w/v) BSA
in PBS with 0.05% (v/v) Tween (PBS-T) for 2 h, followed by incubation with
primary antibodies overnight. SP-B (1:5000 dilution) or SP-C (1:5000 dilution)
antibodies were from Seven Hills Bioreagents72,73. SP-A (1:10,000 dilution) anti-
bodies were kindly supplied by Dr. J. Floros from Penn State University, USA74.
Secondary antibody was anti-rabbit-HRP (Dako) at 1:10,000 dilution for SP-A and
1:5000 dilution for SP-B and SP-C.
To analyze the citH3, 25 μL of each mice BAL-supernatant were mixed with
Laemmli buffer with 4%(v/v) β-mercaptoethanol and heated at 99 °C for 10min.
Samples were loaded into 12% (w/v) acrylamide gels and transferred onto
nitrocellulose membranes. Membranes were blocked as previously described and
incubated with primary anti-citH3 antibody (Abcam ref. #5103) at 1:500 dilution and
secondary anti-rabbit antibody (Dako) 1:5000 dilution. In both cases, bands were
developed with ECL (Millipore) and densitometry analysis was carried out with
ImageJ software.
Statistics and reproducibility. All statistical analyses were performed on
GraphPad Prism 7. For multiple comparisons Two-way ANOVA with Bonferroni
post-test and One-way ANOVA with Tukey’s post-test or t-test were used as
appropriate. All data are presented as mean ± SD. The biological replicates and
applied statistical tests are noted in the respective figure legends. Significant dif-
ferences were considered with a p-value of <0.05(*), <0.01(**), <0.001(***), and
<0.0001(****).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All the source raw data used for generating main and Supplementary Figures are
provided as supplementary excel files.
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